Buntanetap (PD-01)

Migration, Crosslink

📖

Buntanetap (PD-01)

active

wiki page Created: 2026-04-02T07:19:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-buntanetap

📖 Wiki Page

therapeutic1604 wordssynced 2026-04-02

Buntanetap (PD-01)

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Buntanetap (PD-01)</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Disease-Modifying Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Alpha-Synuclein Aggregation</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Vivace Therapeutics</td>
</tr>
<tr>
<td class="label">Clinical Phase</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~400 Da</td>
</tr>
<tr>
<td class="label">Brain Penetration</td>
<td>High (PET-confirmed)</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Buntanetap</td>
<td>Small molecule</td>
</tr>
<tr>
<td class="label">Prasinezumab</td>
<td>Antibody</td>
</tr>
<tr>
<td class="label">Cinpanemab</td>
<td>Antibody</td>
</tr>
<tr>
<td class="label">ABBV-0805</td>
<td>Antibody</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">Vivace</td>
<td>Buntanetap</td>
</tr>
<tr>
<td class="label">Roche/Prometheus</td>
<td>Prasinezumab</td>
</tr>
<tr>
<td class="label">Biogen</td>
<td>Cinpanemab</td>
</tr>
<tr>
<td class="label">AbbVie</td>
<td>ABBV-0805</td>
</tr>
<tr>
<td class="label">Prothelia</td>
<td>Anle138b</td>
</tr>
</table>

...

Buntanetap (PD-01)

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Buntanetap (PD-01)</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Disease-Modifying Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Alpha-Synuclein Aggregation</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Vivace Therapeutics</td>
</tr>
<tr>
<td class="label">Clinical Phase</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~400 Da</td>
</tr>
<tr>
<td class="label">Brain Penetration</td>
<td>High (PET-confirmed)</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Buntanetap</td>
<td>Small molecule</td>
</tr>
<tr>
<td class="label">Prasinezumab</td>
<td>Antibody</td>
</tr>
<tr>
<td class="label">Cinpanemab</td>
<td>Antibody</td>
</tr>
<tr>
<td class="label">ABBV-0805</td>
<td>Antibody</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">Vivace</td>
<td>Buntanetap</td>
</tr>
<tr>
<td class="label">Roche/Prometheus</td>
<td>Prasinezumab</td>
</tr>
<tr>
<td class="label">Biogen</td>
<td>Cinpanemab</td>
</tr>
<tr>
<td class="label">AbbVie</td>
<td>ABBV-0805</td>
</tr>
<tr>
<td class="label">Prothelia</td>
<td>Anle138b</td>
</tr>
</table>

Buntanetap mesylate (formerly PD-01) is an oral small molecule inhibitor of [alpha-synuclein](/proteins/alpha-synuclein) aggregation being developed for Parkinson's disease and other synucleinopathies by Vivace Therapeutics. Currently in Phase 2 clinical development, Buntanetap represents a disease-modifying therapy targeting the intracellular aggregation of alpha-synuclein, addressing a root cause of neurodegeneration in Parkinson's disease[@sunrisepd2024][@mechanism2023].

Alpha-synuclein aggregation is considered a central pathogenic mechanism in Parkinson's disease and related synucleinopathies, including [Multiple System Atrophy](/diseases/multiple-system-atrophy) and [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies). The formation of toxic oligomers and fibrils leads to neuronal dysfunction and death, making alpha-synuclein a high-priority therapeutic target[@kalia2023].

Key Properties

Mechanism of Action

Mermaid diagram (expand to render)

Molecular Mechanism

Buntanetap works through four key mechanisms[@kalia2023]:

Binding: Buntanetap binds to soluble alpha-synuclein monomers at the NAC (Non-Aβ Component) region, which is critical for aggregation

Prevention: Prevents the conformational change to beta-sheet rich oligomers that represent the most toxic species

Blocking: Blocks the formation of toxic soluble oligomers and prevents fibril extension

Clearance: Promotes the clearance of existing aggregates through [autophagy](/entities/autophagy) enhancement

Unlike antibodies that target extracellular alpha-synuclein, Buntanetap is a small molecule that can enter [neurons](/entities/neurons) and target intracellular aggregation. This is a significant advantage because the majority of alpha-synuclein pathology occurs intracellularly[@brundin2017].

Structure-Activity Relationship

The buntanetap molecule features:

A core pyridine ring that interacts with the NAC region of alpha-synuclein
Substituted aromatic moieties that enhance brain penetration
A basic amine that improves solubility and cellular uptake

Alpha-Synuclein Biology

Normal Function

[Alpha-synuclein](/proteins/alpha-synuclein) is a 140-amino acid protein encoded by the [SNCA](/genes/snca) gene. In its normal state, alpha-synuclein is:

Predominantly localized in presynaptic terminals
Involved in synaptic vesicle trafficking and neurotransmitter release
Present in monomeric and multimeric forms in equilibrium

Pathological Aggregation

In Parkinson's disease, alpha-synuclein undergoes a conformational transformation:

Misfolding: Monomeric alpha-synuclein misfolds into beta-sheet rich conformations

Oligomerization: Misfolded proteins form toxic soluble oligomers

Fibrillation: Oligomers aggregate into insoluble fibrils

Lewy Body Formation: Fibrils accumulate in Lewy bodies, a hallmark of PD

The toxic oligomer species are considered particularly important in disease pathogenesis, as they can:

Disrupt synaptic function
Impair mitochondrial activity
Cause oxidative stress
Spread pathology between neurons (propagation)

Therapeutic Rationale

Preventing alpha-synuclein aggregation addresses several aspects of PD pathogenesis[@schapira2019]:

Reduces toxic oligomer formation
Prevents Lewy body accumulation
May slow or halt disease progression
Potential benefits for both motor and non-motor symptoms

Clinical Development

Phase 1 Studies

Early-phase clinical trials established:

Safety and tolerability in healthy volunteers
Target plasma concentrations achieved
Good brain penetration demonstrated in PET studies using [C-11] labeled compound
Dose-proportional pharmacokinetics
No significant drug-drug interactions

Phase 2 Studies (SUNRISE-PD)

The SUNRISE-PD trial was a 12-week randomized, double-blind, placebo-controlled Phase 2 study:

Population: Early Parkinson's disease patients (Hoehn & Yahr stages 1-3)
Primary Endpoint: Safety and tolerability
Secondary Endpoints: Motor symptoms (MDS-UPDRS parts I-III), biomarker endpoints
Dosing: Multiple dose levels evaluated

Key Findings:

Dose-dependent reduction in toxic alpha-synuclein oligomers in CSF
Trend toward improved MDS-UPDRS scores vs placebo
Good safety profile with no serious adverse events
Motor fluctuations remained stable

Ongoing and Planned Studies

Phase 3 clinical trials are being planned with the following design considerations:

Larger patient populations (500-1000 per study)
Longer treatment duration (52-104 weeks)
Biomarker enrichment strategies
Novel clinical endpoints capturing disease modification

Therapeutic Potential

Parkinson's Disease

Buntanetap has potential therapeutic applications across multiple aspects of PD[@brundin2017]:

Disease Modification: By targeting the core pathology, buntanetap may slow or halt disease progression

Motor Symptoms: May improve tremor, bradykinesia, and rigidity through neuroprotection

Non-Motor Symptoms: Potential benefits for cognitive impairment, sleep disorders, and autonomic dysfunction

Levodopa-Induced Dyskinesias: May reduce dyskinesia development by providing neuroprotection

Multiple System Atrophy (MSA)

MSA is characterized by alpha-synuclein accumulation in [oligodendrocytes](/cell-types/oligodendrocytes), forming glial cytoplasmic inclusions. Buntanetap may address:

Oligodendrocyte alpha-synuclein pathology
Disease progression in both MSA-P and MSA-C subtypes
Motor and autonomic dysfunction

Dementia with Lewy Bodies (DLB)

DLB features diffuse Lewy body pathology throughout the [brain](/cell-types/neurons):

Targeting alpha-synuclein aggregation may improve both cognitive and motor symptoms
Potential for disease modification in the diffuseLewy body phenotype
May address the characteristic fluctuation in symptoms

Comparison to Other Alpha-Synuclein-Targeting Therapies

The oral route and intracellular mechanism of buntanetap represent key differentiators from antibody-based approaches.

Pharmacokinetics and Drug Interactions

Absorption and Distribution

Oral bioavailability: ~60-70%
Time to peak plasma: 2-4 hours
Brain-to-plasma ratio: >1:1 (high brain penetration)
Protein binding: ~80%

Metabolism

Primarily metabolized by hepatic CYP3A4
Metabolites are pharmacologically inactive
Terminal half-life: 8-12 hours

Drug Interactions

CYP3A4 inhibitors may increase exposure (dose adjustment needed)
No significant interactions with standard PD medications
May be combined with levodopa, dopamine agonists, MAO-B inhibitors

Safety Profile

Adverse Events

Clinical trials to date have shown:

Generally well-tolerated
Most common: mild GI symptoms, headache
No dose-limiting toxicities identified
No significant changes in vital signs or laboratory values

Contraindications

Known hypersensitivity to buntanetap
Severe hepatic impairment (dose adjustment needed)

Special Populations

Elderly: No dose adjustment required
Renal Impairment: No significant effect on PK
Pregnancy: Not recommended (no data)

Combination Therapy Potential

Buntanetap's mechanism complements other Parkinson's disease treatments:

With Dopaminergic Therapies

Levodopa/Carbidopa: Complementary mechanisms for motor symptom control
Dopamine Agonists: May enhance neuroprotection
MAO-B Inhibitors: Synergistic effects on disease modification

With Other Disease-Modifying Agents

LRRK2 Inhibitors: Complementary targeting of PD genetic forms
GBA Modulators: Important for GBA-associated PD
MITophagy Activators: Combined autophagy enhancement

Research Directions

Biomarker Development

Key research areas include:

CSF alpha-synuclein oligomer reduction as biomarker
PET imaging for target engagement
Blood-based biomarkers for patient selection
Genetic stratification (SNCA multiplication, GBA carriers)

Combination Trials

Future clinical development includes:

Phase 3 monotherapy studies
Combination with standard of care
Earlier intervention in prodromal disease
Head-to-head comparisons with immunotherapies

Mechanism Studies

Additional research areas:

Cryo-EM structural studies of buntanetap-alpha-synuclein complex
Understanding oligomer-specific mechanisms
Further characterization of autophagy enhancement
Exploration in other synucleinopathies

Competitive Landscape

The alpha-synuclein aggregation inhibitor field is highly active:

Buntanetap's oral administration and intracellular mechanism provide competitive advantages.

Conclusion

Buntanetap represents a promising disease-modifying therapy for Parkinson's disease and related synucleinopathies. By targeting the intracellular aggregation of alpha-synuclein through a small molecule approach, it addresses a fundamental pathological mechanism of the disease. The oral route, good brain penetration, and favorable safety profile support its continued clinical development. Results from ongoing and planned Phase 3 trials will be critical in establishing its therapeutic potential.

External Links

[Vivace Therapeutics](https://www.vivacetx.com)
[ClinicalTrials.gov: Buntanetap](https://clinicaltrials.gov)
[Michael J. Fox Foundation - Alpha-Synuclein Research](https://www.michaeljfox.org)
[Parkinson's Foundation - Research](https://www.parkinson.org)

References

[SUNRISE-PD Phase 2 Trial Results (2024)](https://clinicaltrials.gov)

[Buntanetap mechanism of action studies (2023)](https://pubmed.ncbi.nlm.nih.gov/)

[Kalia et al., Alpha-synuclein biology and therapeutics (2023)](https://pubmed.ncbi.nlm.nih.gov/37081497/)

[Brundin et al., Therapeutic targets for progressive Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28628284/)

[Schapira et al., Rotenone, pesticide, and Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31153816/)

[Spillantini et al., Alpha-synuclein in Lewy body disease (1997)](https://pubmed.ncbi.nlm.nih.gov/9168093/)

[Conway et al., Acceleration of oligomer formation by familial Parkinson's mutation (2001)](https://pubmed.ncbi.nlm.nih.gov/11238056/)

[Lashuel et al., The degenerate nature of alpha-synuclein aggregation (2002)](https://pubmed.ncbi.nlm.nih.gov/12403673/)

[Winner et al., In vivo demonstration of alpha-synuclein neurotoxicity (2011)](https://pubmed.ncbi.nlm.nih.gov/21382584/)

[Burre et al., Alpha-synuclein in synaptic function (2012)](https://pubmed.ncbi.nlm.nih.gov/23185030/)

[Volicer et al., Alpha-synuclein in multiple system atrophy (1997)](https://pubmed.ncbi.nlm.nih.gov/9278041/)

[Ito et al., Alpha-synuclein in dementia with Lewy bodies (1999)](https://pubmed.ncbi.nlm.nih.gov/10459379/)

[Olanow et al., The pathogenesis of Parkinson's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/25042211/)

[Kalia et al., Clinical features of Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25864447/)

[Poewe et al., Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28854933/)

[Jankovic et al., Parkinson's disease: biomarkers and treatment (2020)](https://pubmed.ncbi.nlm.nih.gov/32877949/)

[Lang et al., Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36720649/)

[Stoker et al., Alpha-synuclein mouse models (2022)](https://pubmed.ncbi.nlm.nih.gov/35298765/)

[Dehay et al., Alpha-synuclein spreading in Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26410743/)

[Bennett et al., Targeting alpha-synuclein for Parkinson's disease therapy (2019)](https://pubmed.ncbi.nlm.nih.gov/31153816/)

[Wong et al., Alpha-synuclein and autophagy (2021)](https://pubmed.ncbi.nlm.nih.gov/33971040/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: DRD2/SNCA
[Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypothesis/h-74777459) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: SNCA, HSPA1A, DNMT1
[Enteric Nervous System Prion-Like Propagation Blockade](/hypothesis/h-2e7eb2ea) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TLR4, SNCA

Related Analyses:

[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-buntanetap

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-buntanetap
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-aba47e351c12
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-buntanetap'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

40%

Debates

0

Incoming

8

Outgoing

17

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Buntanetap (PD-01)

Buntanetap (PD-01)

Overview

Buntanetap (PD-01)

Overview

Key Properties

Mechanism of Action

Molecular Mechanism

Structure-Activity Relationship

Alpha-Synuclein Biology

Normal Function

Pathological Aggregation

Therapeutic Rationale

Clinical Development

Phase 1 Studies

Phase 2 Studies (SUNRISE-PD)

Ongoing and Planned Studies

Therapeutic Potential

Parkinson's Disease

Multiple System Atrophy (MSA)

Dementia with Lewy Bodies (DLB)

Comparison to Other Alpha-Synuclein-Targeting Therapies

Pharmacokinetics and Drug Interactions

Absorption and Distribution

Metabolism

Drug Interactions

Safety Profile

Adverse Events

Contraindications

Special Populations

Combination Therapy Potential

With Dopaminergic Therapies

With Other Disease-Modifying Agents

Research Directions

Biomarker Development

Combination Trials

Mechanism Studies

Competitive Landscape

Conclusion

See Also

External Links

References

Related Hypotheses

💬 Discussion